The 1989 Nobel prize winner in Physiology/Medicine, Prof. Bishop JM, Qu J and others from G.W. Hooper Foundation, University of California at San Francisco, San Francisco, California 94143, USA has published a research paper in the 11 June 2012 J Cell Biol (I.F: >10) stating that “Nucleostemin maintains self-renewal of embryonic stem cells and promotes reprogramming of somatic cells to pluripotency.”
Based on this this finding, Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports that: Interleukin-based Anti-Cancer Stem cell therapy: Interleukin-1β (IL-1β) suppresses the expression of Nucleoplasmin and reprogramming of somatic cells via down regulation of its target gene. This study suggests that Interleukin-1β, by suppressing the expression of Nucleoplasmin, it may increase the expression of a number of tumor suppressor genes. Thereby, it may inhibit self-renewal of ESEs. Thus, pharmacological formulations encompassing “Interleukin-1β or its activators” may be used to target cancer stem cells and cure human cancer.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Interleukin-based Anti-Cancer Stem cell therapy: Interleukin-1β (IL-1β) suppresses the expression of Nucleoplasmin and reprogramming of somatic cells via down regulation of its target gene, 9/October/2014, 5.06 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation